Vnitr Lek 2017, 63(4):234-235 | DOI: 10.36290/vnl.2017.049

Novinky v liečbe srdcového zlyhávania - editorial

Ján Murín
I. interná klinika LF UK a UNB, Nemocnica Staré mesto, Bratislava, Slovenská republika

Received: March 9, 2017; Published: April 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Murín J. Novinky v liečbe srdcového zlyhávania - editorial. Vnitr Lek. 2017;63(4):234-235. doi: 10.36290/vnl.2017.049.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Pocock SJ, Ariti AC, McMurray JJV et al. Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. Eur Heart J 2013; 34(19): 1404-1413. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehs337>. Go to original source... Go to PubMed...
    2. Souček F, Novák J. Novinky v léčbě srdečního selhání. Vnitř Lék 2017; 63(4): 255-264. Go to original source... Go to PubMed...
    3. McMurray JJV, Packer M, Desain AS et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371(11): 993-1004. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1409077>. Go to original source... Go to PubMed...
    4. Zile MR, Claggett BL, Prescott MF et al. Prognostic implications of changes in N-terminal pro-B-type natriuretic peptide patients with heart failure. J Am Coll Cardiol 2016; 68(22): 2425-2436. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2016.09.931>. Go to original source... Go to PubMed...
    5. Zinman B, Wanner C, Lachin JM et al. [EMPA-REG OUTCOME Investigators].Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373(22): 2117-2128. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1504720>. Go to original source... Go to PubMed...
    6. Murín J. Empagliflozín (inhibítor sodíkovo-glukózového kotransportéra 2) - nádej pre diabetikov 2. typu. Cardiol Lett 2016; 25(1): 45-48.
    7. Nohria A, Tsang SW, Fang JC et al. Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. J Am Coll Cardiol 2003; 41(10): 1797-1804. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.